SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC

Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology, 20(11), 653–663. https://doi.org/10.2217/fon-2022-1249
Authors:
Elena Elez
Scott Kopetz
Josep Tabernero
Tanios Bekaii-Saab
Julien Taieb
Takayuki Yoshino
Gulam Manji
Kathrine Fernandez
Antonello Abbattista
Xiaosong Zhang
Van K Morris
Affiliated Authors:
Gulam Manji
Subjects:
Colorectal Neoplasms (MeSH)
Colonic Neoplasms (MeSH)
Antibodies, Monoclonal, Humanized (MeSH)
Neoplastic Syndromes, Hereditary (MeSH)
Sulfonamides (MeSH)
Brain Neoplasms (MeSH)
Carbamates (MeSH)
Author Keywords:
braf v600
msi-h
cetuximab
dmmr
encorafenib
immunotherapy
metastatic colorectal cancer
pembrolizumab
targeted therapy
triplet combination therapy
elink
Publication Type:
Article
Unique ID:
10.2217/fon-2022-1249
PMID:
37815847
DOI:
10.2217/fon-2022-1249
Journal:
Future Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: